Grace Therapeutics, Inc. (GRCE) Price Target Analysis
Analyst Rating:
Based on 0 analystsNo Target Data
GRCE trades at Wall Street's consensus target of —.
Current Price$2.34
Average Target—
Low—
Median—
High—
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth—
Analyst Spread—
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes GRCE achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of multiple Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
GRCE Price Target Analysis
Updated June 28, 2026As of June 28, 2026, Grace Therapeutics, Inc. (GRCE) has a Wall Street consensus price target of N/A, based on estimates from 0 covering analysts. The company has a market capitalization of $38M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, GRCE trades at a trailing P/E of -5.0x.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+38.9%
Industry Consensus
Avg Forward P/E
43.6x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RAREUltragenyx Pharmaceutical Inc. | $3.0B | $30.77 | $48.36 | +57.2% | Buy | — | 33 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 ACADACADIA Pharmaceuticals Inc. | $4.3B | $25.32 | $33.67 | +33.0% | Buy | 65.1x | 37 |
 PTCTPTC Therapeutics, Inc. | $7.0B | $84.43 | $95.83 | +13.5% | Buy | 95.3x | 26 |
 ARVNArvinas, Inc. | $516M | $8.00 | $14.75 | +84.4% | Buy | — | 26 |
 SRPTSarepta Therapeutics, Inc. | $1.8B | $16.85 | $25.14 | +49.2% | Buy | 4.8x | 54 |
 BMRNBioMarin Pharmaceutical Inc. | $11.3B | $59.00 | $89.21 | +51.2% | Buy | 11.9x | 41 |
 ALNYAlnylam Pharmaceuticals, Inc. | $38.9B | $291.37 | $454.27 | +55.9% | Buy | 38.9x | 52 |
 KRYSKrystal Biotech, Inc. | $11.0B | $372.25 | $336.40 | -9.6% | Buy | 48.5x | 17 |
 RCKTRocket Pharmaceuticals, Inc. | $355M | $3.25 | $5.00 | +53.8% | Buy | — | 19 |
GRCE — Frequently Asked Questions
Quick answers to the most common questions about buying GRCE stock.
What is the GRCE stock price target for 2026?
The consensus price target for GRCE is $N/A, close to the current price of $2.34 (N/A% implied move). Based on 0 analyst estimates, the stock appears fairly valued near current levels.
Is GRCE a buy, sell, or hold?
GRCE has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
Is GRCE stock overvalued or undervalued?
GRCE's current price is $2.34 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
How high can GRCE stock go?
The most bullish Wall Street analyst has a price target of $N/A for GRCE, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover GRCE stock?
GRCE is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the GRCE stock forecast?
The 12-month GRCE stock forecast based on 0 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "N/A".
Should I buy GRCE stock?
GRCE appears fairly valued according to analysts, with a "N/A" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do GRCE price targets vary so much?
GRCE analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare